ReviewNano convergence2026
Safe and sustainable by design (SSbD) for nanotechnology: scientific foundations, global policy perspectives, and industrial practice.
Review in Nano convergence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
Abstract
Safe and Sustainable by Design (SSbD) is emerging as a transformative framework for integrating safety and sustainability with functionality in nanotechnology. This review provides a unified perspective on SSbD, bridging its scientific foundations, global policy developments, and industrial implementation. We highlight how advances in mechanistic understanding of nanomaterial-biological interactions enable earlier and more predictive safety assessment, supporting informed material design. At the policy level, evolving regulatory and governance approaches across regions are shaping the integration of sustainability and safety requirements. From an industrial perspective, SSbD is driving innovation in material substitution, process optimization, and lifecycle-oriented design. Despite this progress, challenges remain in standardization, data integration, and alignment between regulatory frameworks and industrial practice. This work positions SSbD as a central paradigm for enabling responsible innovation and accelerating the transition toward safer and more sustainable nanotechnologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.